In advanced cancers including COAD (stages III-IV, p = 0.038), HNSC (stages III-IV, p = 0.005), KICH (stages II-IV, p = 0.012), and READ (stages II-IV, p = 0.013), longer OS was achieved in patients with elevated TMC5 expression, while for KIRC (stages III-IV, p < 0.001), melanoma (stages II-IV, p = 0.036), and LIHC (stage III-IV, p = 0.019), highly expressed TMC5 was correlated to shorter OS (Figure 4). This evidence concerns the gene TMC5 and melanoma.